Andrew Hattersley - Curriculum Vitae#

Degrees

• 1997 D.M. University of Oxford “The genetics of Type 2 diabetes”
  
• 1984 BM BCh University of Oxford (Postgraduate Medical Prize)
  
• 1981 B.A. University of Cambridge (2:1 Medical Sciences), UK

Grant funding

• Total of > £92 million from 103 individual grants
  

Present major funding

• 2022 - 2029 Wellcome Trust Collaborative grant PI £3,500,000
  
• 2022 - 2027 MRC Project grant PI £1,000,000
  
• 2018 - 2022 NIHR Global Health co PI £2,450,000.
  
• 2019 - 2023 Research England Enabling Excellence in England (E3) PI £5,984,000
  
• 2016 - 2026 EASD- Novo Nordisk Foundation Diabetes Prize for Excellence PI Euro 500,000
  
• 2017 - 2022 NIHR Funding for Clinical Research Facilities (Co-PI) £5,738,298

Significant recent funding

• 2012 - 2021 Wellcome Trust Senior Investigator (PI joint with Prof Ellard) £2,870,00
  
• 2012 - 2021 MRC Stratified medicine initiative PI £6,000,000
  
• 2012 - 2019 EU IMI (coI) (46M Euro total c £5M Euro to Exeter)

Publications

• >650 peer reviewed publications including Science, Nature, Nature Genetics, NEJM, Lancet, JAMA.
  
• From Google Scholar >123,000 citations, H index 160
  
• Authored the chapter on monogenic diabetes in all 4 major textbooks on diabetes.
  

Presentations

• Over 370 invited presentations at national and international conferences
  
• Has given plenary and opening invited presentations at all major international conferences for Diabetes (IDF, ISPAD, ADA, EASD) Endocrinology (ES, IES, EES, PES), Beta-cell science (EMBO, EASD, Gordon, Keystone. and Coldsprings harbor) and genetics (ASHG, ESHG)
  

Current Research Commitments:

Prof Hattersley, runs a 25 person research team in Exeter. This includes staff working in gene discovery, human physiology, clinical trials, data informatics, modelling for diagnosis and treatment response and implementation research. His work emphasises translating scientific advances in genetics into improvement in diagnosis and clinical care in diabetes. A major part of his present work involves using his experience of developing precision medicine into monogenic diabetes to develop precision medicine approaches in Type 2 and Type 1 diabetes.